New insider activity at Rocket Pharmaceuticals ( (RCKT) ) has taken place on October 16, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
John Militello, the VP of Finance, Treasurer, and Principal Accounting Officer at Rocket Pharmaceuticals, has recently sold 28,918 shares of the company’s stock. This transaction was valued at $114,550.
Recent Updates on RCKT stock
Rocket Pharmaceuticals recently announced that the FDA accepted the resubmission of their Biologics License Application for KRESLADI™, a gene therapy for severe Leukocyte Adhesion Deficiency-I, with a PDUFA date set for March 28, 2026. This development could potentially enhance their market positioning if approved. However, the company also voluntarily withdrew its Biologics License Application for RP-L102, an investigational gene therapy for Fanconi Anemia, due to strategic prioritization and not due to safety or efficacy concerns. This decision, along with the company’s financial risks and ongoing cash burn, has led to a lowered price target by analysts, reflecting the challenges Rocket Pharmaceuticals faces in its development phase. The company’s strategic shifts and regulatory challenges have contributed to a Hold rating with a $7.00 price target, as analysts assess the company’s focus on programs with clearer regulatory and commercial pathways.
Spark’s Take on RCKT Stock
According to Spark, TipRanks’ AI Analyst, RCKT is a Underperform.
Rocket Pharmaceuticals’ overall score reflects its position as a biotechnology firm in the development phase, with significant financial risks due to its lack of revenue and reliance on external financing. Technical indicators suggest potential volatility, while the negative P/E ratio highlights current valuation challenges. The company’s strong equity position is a positive factor, but ongoing cash burn remains a critical concern.
To see Spark’s full report on RCKT stock, click here.
More about Rocket Pharmaceuticals
YTD Price Performance: -66.67%
Average Trading Volume: 3,942,858
Technical Sentiment Signal: Sell
Current Market Cap: $457.5M